Epoch Investment Partners Inc. Sells 21,131 Shares of Charles River Laboratories International, Inc. $CRL

Epoch Investment Partners Inc. lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 77.0% in the first quarter, Holdings Channel reports. The fund owned 6,308 shares of the medical research company’s stock after selling 21,131 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Charles River Laboratories International were worth $1,088,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Tema Etfs LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $42,000. Sfam LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $43,000. Activest Wealth Management lifted its stake in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Charles River Laboratories International by 98.0% in the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.1%

Charles River Laboratories International stock opened at $226.38 on Monday. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $238.85. The firm has a market capitalization of $10.90 billion, a price-to-earnings ratio of -60.21, a P/E/G ratio of 2.52 and a beta of 1.40. The firm has a 50 day moving average of $198.80 and a 200 day moving average of $187.36. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Analysts Set New Price Targets

CRL has been the subject of several recent research reports. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Evercore reiterated an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Finally, Mizuho upped their price objective on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $220.75.

Insider Activity at Charles River Laboratories International

In related news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.